Myrtle Potter is one of America’s foremost healthcare leaders and innovators. She is Vant Operating Chair at Roivant Sciences, a global biopharmaceutical company that currently has thirty investigational drugs in eleven therapeutic areas being tested in over fifty clinical trials across the Roivant family of companies. She is also founder of Myrtle Potter & Company, LLC, a healthcare and life science advisory firm that has operated since 2005.
Myrtle was president and chief operating officer of Genentech, Inc. where, from 2000 to 2005, she led the company through one of the most successful periods in its history. Genentech achieved record sales and earnings growth during each of the five years she led the company and sales grew more than five-fold to over $5 billion over the same period. Under her leadership the company launched seven breakthrough products including Avastin™, the blockbuster cancer treatment. During her tenure she served on the Executive Committee of the Company and co-chaired the Product Portfolio Committee which made all investment and “go/no go” decisions for Genentech’s drug pipeline.
Myrtle is also an independent director of Rite Aid Corporation, Liberty Mutual Holding Company, Proteus Digital Health, Insmed and Axsome. She also serves on the University of Chicago Board of Trustees. Formerly she served on the boards of Amazon, FoxHollow Technologies, eV3, Medco Health Solutions and Express Scripts
Myrtle was named to FORTUNE Magazine’s list of Most Powerful Women in Business on three separate occasions. Her business and leadership has been recognized by BusinessWeek, The Wall Street Journal, FORTUNE Magazine, TIME Magazine, Forbes, Black Enterprise Magazine, Savoy and Harvard Business Review. Myrtle earned a B.A. from The University of Chicago.
Learn more about the CNS Summit and follow us on Twitter (@cnssummit). Listen to this episode on Health Podcast Network.
October 31, 2019